↓ Skip to main content

Bone Density After Teriparatide Discontinuation in Premenopausal Idiopathic Osteoporosis

Overview of attention for article published in JCEM, September 2015

Mentioned by

twitter
1 X user

Readers on

mendeley
48 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
Bone Density After Teriparatide Discontinuation in Premenopausal Idiopathic Osteoporosis
Published in
JCEM, September 2015
DOI 10.1210/jc.2015-2829
Pubmed ID
Authors
Abstract

Without antiresorptive therapy, postmenopausal women lose bone mass after teriparatide discontinuation; estrogen treatment prevents bone loss in this setting. It is not known whether premenopausal women with regular menses lose bone mass after teriparatide discontinuation. To test our hypothesis that normally menstruating premenopausal women with idiopathic osteoporosis (IOP) will maintain teriparatide-associated BMD gains after medication cessation. 21 premenopausal IOP women, previously enrolled in an open-label pilot study of teriparatide (20mcg for 18-24mo), had substantial BMD increases at the lumbar spine (LS; 10.8±8.3%), total hip (TH; 6.2±5.6%) and femoral neck (FN; 7.6±3.4%). For this study, BMD was remeasured 2.0±0.6 years after teriparatide cessation. 15 women, who had gained 11.1±7.2% at LS and 6.1±6.5% at TH and were premenopausal at teriparatide completion, were followed without antiresorptive treatment. Two years after completing teriparatide, BMD declined by 4.8±4.3% (p=0.0007) at the LS. In contrast, BMD remained stable at the FN (-1.5±4.2%) and total hip (-1.1±3.7%). Those who sustained LS bone loss >3% (-7.3±2.9%; n=10), did not differ from those with stable LS BMD (0.1±1.1%; n=5) with regard to baseline BMI, BMD at any site, or duration of follow-up, but were significantly older at re-evaluation (46±3 vs 38±7; p=0.046), had larger increases in LS BMD during teriparatide treatment and higher cancellous bone remodeling on transiliac biopsy at baseline and completion of teriparatide treatment. Serum bone turnover markers (BTMs) did not differ at baseline or teriparatide completion, but tended to be higher at the re-evaluation timepoint in those with post-teriparatide bone loss. These findings lead us to conclude that premenopausal women with IOP, particularly those over 40, may require antiresorptive treatment to prevent bone loss after teriparatide.

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 48 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
Unknown 48 100%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Student > Master 8 17%
Other 7 15%
Student > Ph. D. Student 6 13%
Student > Bachelor 4 8%
Professor 4 8%
Other 5 10%
Unknown 14 29%
Readers by discipline
Readers by discipline Count As %
Medicine and Dentistry 16 33%
Nursing and Health Professions 3 6%
Agricultural and Biological Sciences 3 6%
Pharmacology, Toxicology and Pharmaceutical Science 1 2%
Biochemistry, Genetics and Molecular Biology 1 2%
Other 6 13%
Unknown 18 38%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 February 2016.
All research outputs
#28,999,249
of 34,826,706 outputs
Outputs from JCEM
#19,358
of 21,265 outputs
Outputs of similar age
#237,195
of 304,475 outputs
Outputs of similar age from JCEM
#103
of 115 outputs
Altmetric has tracked 34,826,706 research outputs across all sources so far. This one is in the 9th percentile – i.e., 9% of other outputs scored the same or lower than it.
So far Altmetric has tracked 21,265 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.9. This one is in the 5th percentile – i.e., 5% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 304,475 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 11th percentile – i.e., 11% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 115 others from the same source and published within six weeks on either side of this one. This one is in the 5th percentile – i.e., 5% of its contemporaries scored the same or lower than it.